Attached files
file | filename |
---|---|
10-Q - SKYSTAR BIO-PHARMACEUTICAL CO | v185379_10q.htm |
EX-31.2 - SKYSTAR BIO-PHARMACEUTICAL CO | v185379_ex31-2.htm |
EX-32.2 - SKYSTAR BIO-PHARMACEUTICAL CO | v185379_ex32-2.htm |
EX-32.1 - SKYSTAR BIO-PHARMACEUTICAL CO | v185379_ex32-1.htm |
Exhibit
31.1
CERTIFICATION
I, Weibing Lu, certify that:
1. I have reviewed this
Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical
Company;
2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the
circumstances under which
such statements were made, not misleading with respect to the period covered by
this report;
3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods
presented in this report;
4. The registrant’s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:
a. Designed such disclosure controls and
procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which
this report is being prepared;
b. Designed such internal control over
financial reporting, or caused such internal control over financial reporting to
be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principals;
c. Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and presented in this report
our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such
evaluation; and
d. Disclosed in this report any change in
the registrant’s internal control over financial
reporting that occurred during the registrant’s most recent fiscal quarter (the
registrant’s fourth fiscal quarter in the case of
an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial
reporting; and
5. The registrant’s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over
financial reporting to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons
performing the equivalent functions):
a. All significant deficiencies and
material weaknesses in the design or operation of internal controls over
financial reporting which are reasonably likely to adversely affect the
registrant’s ability to record, process, summarize
and report financial information; and
b. Any fraud, whether or not material, that
involves management or other employees who have a significant role in the
registrant’s internal control over financial
reporting.
Date: May
17, 2010
|
/s/ Weibing Lu
|
|
Weibing
Lu
|
||
Chief
Executive Officer
|
||
(Principal
Executive Officer)
|